Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the registrant     Filed by a party other than the registrant 
Check the appropriate box: 
 Preliminary Proxy Statement
 Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material Pursuant to §240.14a-12
MIMEDX GROUP, INC.
(Name of registrant as specified in its charter)
Payment of the filing fee (check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
(2)Aggregate number of securities to which transaction applies:
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)Amount previously paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing party:
(4)Date filed:




On May 3, 2021, the Registrant published comments on various social media sites:
Twitter:

Vote the WHITE proxy card today to protect your investment in MDXG. [https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-files-definitive-proxy-materials-and-mails-letter-0]

The MIMEDX Board has a clear plan for value creation, read more about what we are doing to protect your investment. [https://votemimedx.com]

The MIMEDX transformation is well underway but there is more work to be done. Learn more about how our company’s leaders are implementing our transformative strategy. [https://votemimedx.com]

Our strategy is driving performance and significant shareholder returns. Know the facts before you vote the WHITE proxy card FOR MIMEDX’s qualified candidates. [https://votemimedx.com]

Our leadership team’s actions have driven stock price appreciation of 237% since Mr. Wright assumed the role of CEO. Learn more about why our team is the right team to lead MIMEDX. [https://votemimedx.com]

Facebook:

Your Board of Directors and management team have taken decisive and positive actions to create
shareholder value by transforming MIMEDX into a stronger company that is well positioned to capitalize on the growing opportunities in the regenerative medicine industry. Learn more about why we have the right team leading MIMEDX’s transformation. [https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-files-definitive-proxy-materials-and-mails-letter-0]

You have an important decision to make regarding the future of your investment in MIMEDX. Ensure the
Board and management team have the opportunity to continue the successful execution of our clear
strategic plan to accelerate our late-stage pipeline and achieve our stated top line growth objectives in our core business. Your vote on the WHITE proxy card is critical, no matter how many shares you own. Learn more about how you can support our directors and our strategy here. [https://votemimedx.com]